Krish Patel, MD

Articles

Dr. Patel on Emerging Therapeutic Strategies in MCL

March 20th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).

Dr. Patel Discusses Zanubrutinib in MCL

March 11th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Patel on Induction in Patients With Mantle Cell Lymphoma

February 19th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Dr. Patel on Ibrutinib in Real-World Setting Versus Clinical Trials

February 13th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses a study looking at real-world benefit of BTK inhibitors versus what is seen in clinical trials for patients with mantle cell lymphoma.

Dr. Patel Discusses Promise of Acalabrutinib in MCL

January 15th 2019

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses the promise of acalabrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Patel on Differences Between BTK Inhibitors in MCL

January 9th 2019

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses differences between BTK inhibitors in mantle cell lymphoma (MCL).

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL

December 11th 2018

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).